| COVID-19 Vaccine |
1 |
1 |
| Vaccines |
0 |
0.93 |
| COVID-19 |
0 |
0.79 |
| Severe Acute Respiratory Syndrome |
0 |
0.77 |
| Biologic Therapy |
0 |
0.61 |
| Pandemic |
0 |
0.99 |
| Antigens |
0 |
0.26 |
| Dorsum |
0 |
0.26 |
| Outbreak |
0 |
0.26 |
| Acute Respiratory Distress Syndrome |
0 |
0.17 |
| Diversity |
0 |
0.17 |
| Hospital |
0 |
0.17 |
| Allergy |
0 |
0.09 |
| Biomedical Technology |
0 |
0.09 |
| Face |
0 |
0.09 |
| Genetics |
0 |
0.09 |
| Jobs |
0 |
0.09 |
| Massachusetts |
0 |
0.09 |
| Nasopharyngitis |
0 |
0.09 |
| Nevus |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Students |
0 |
0.09 |
| T-Lymphocyte |
0 |
0.09 |
| Wisconsin |
0 |
0.09 |
| Otolaryngology |
0 |
0.05 |
| Social Determinants of Health |
0 |
0.04 |
| Medical Life |
0 |
0.03 |
| Genomic Medicine |
0 |
0.02 |